3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Liver Neoplasms
3
Cholangiocarcinoma
3
Biliary Tract Neoplasms
3
Bile Duct Neoplasms
2
Acrocephalosyndactylia
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
Capecitabine
77
pembrolizumab
70
Oxaliplatin
68
Cisplatin
56
Fluorouracil
52
Paclitaxel
41
Trastuzumab
37
Nivolumab
35
Leucovorin
27
Docetaxel
27
Irinotecan
22
Ramucirumab
20
Gemcitabine
15
Bevacizumab
15
S 1 (combination)
14
Carboplatin
13
atezolizumab
12
apatinib
12
fludarabine
11
Cyclophosphamide
11
tislelizumab
10
Drug Therapy
10
Injections
8
130-nm albumin-bound paclitaxel
8
trastuzumab deruxtecan
7
durvalumab
7
Ipilimumab
7
Folfox protocol
7
Albumin-Bound Paclitaxel
7
titanium silicide
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Stomach Neoplasms
×
derazantinib
×
Clear all
NCT04604132
2024-04-04
FIDES-03
Basilea Pharmaceutica
Phase 1/2
Terminated
47 enrolled
22 charts